Moderna, Inc. (MRNA) Stock Analysis — Probabli.AI
AI-powered analysis for MRNA (Moderna, Inc.): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment. Latest AI outlook: Neutral.
Last price: $54.82 · Market cap: $39.8B · AI outlook: Neutral
Moderna, Inc. is poised to benefit from its innovative mRNA platform and leadership in vaccine development, though faces challenges from competitive and regulatory fronts. Its pioneering advancements in mRNA applications beyond COVID-19 represent substantial growth opportunities. However, the market's cautious stance is understandable, given recent analyst downgrades and regulatory hurdles. The…
Probabilistic 1-Year Outlook
- Bull 30% · Neutral 45% · Bear 25%
- 1-year price estimates — P10: $42 / P50: $55 / P90: $70
- Despite strong fundamentals like an impressive revenue growth estimate and recent earnings beat streak, the analyst consensus suggests skepticism, likely due to competitive pressures and regulatory concerns. The current…
5-Year Outlook
- Bull 40% · Neutral 35% · Bear 25%
- 5-year price estimates — P10: $50 / P50: $85 / P90: $150
SWOT Highlights
- Strength: Leading mRNA technology platform
- Strength: Strong recent EPS beats
- Risk: High reliance on COVID-19 vaccines
- Risk: Negative current EPS estimate
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
23 Wall Street analysts rate MRNA a HOLD with a mean price target of $45.5.
Last analyzed · Model: gpt-4o. How this forecast works · Accuracy & validation.
MRNA forecast details · MRNA sentiment details
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.